OPSS Opens First Regulatory Sandbox for Bioengineered Cosmetic Ingredients

The UK's Office for Product Safety and Standards has opened the first pilot under its new Product Regulation Sandbox programme, inviting cosmetics manufacturers to test how novel bioengineered ingredients would be assessed under the GB Cosmetics Regulation before they reach a formal application. Guidance for the Cosmetics Sandbox: Bioengineered Ingredients was published on 16 June 2026, and the expression-of-interest window for businesses closes 4 December 2026.

The sandbox targets a specific slice of the ingredient supply chain: companies producing cosmetic ingredients through precision fermentation, synthetic biology, or cell culture, categories that already underpin commercial products such as Neossance's fermentation-derived squalane, used in formulations sold by The Ordinary, alongside fermentation-produced hyaluronic acid and lab-grown collagen-like proteins. OPSS says participants get direct access to its regulatory and scientific staff to work through safety-assessment evidence and uncertainty specific to these technologies, while the regulator in turn collects intelligence to shape future policy on how the GB Cosmetics Regulation should treat them.

The pilot lands alongside a parallel and less permissive strand of OPSS activity. On 27 November 2025 the regulator notified the World Trade Organization of new Annex II restrictions and bans covering 16 CMR substances, including TPO, clothianidin, and tetrabromobisphenol-A, taking effect 15 August 2026. Read together, the two moves describe a regulator tightening controls on ingredients already deemed hazardous while simultaneously building a low-friction entry point for ingredients it has not yet had to classify at all, a split approach to the same GB Cosmetics Regulation.

Scale gives the sandbox context: OPSS's cosmetics notification database, the SCPN, had logged 861,686 product notifications from 24,112 Responsible Persons as of 28 May 2026, a market the regulator is now trying to keep pace with as ingredient science moves faster than conventional rulemaking. The Cosmetic, Toiletry and Perfumery Association, the UK trade body, argued in a December 2024 manifesto that beauty should be regulated as a life-sciences sub-sector with sector-specific, risk-based oversight rather than folded into broader chemical or consumer-product regimes. The sandbox reads as a direct answer to that ask, though OPSS has not published a CTPA statement crediting the association's lobbying for the programme's design.

OPSS is not the first UK regulator to run this kind of experiment. The Food Standards Agency and Food Standards Scotland are roughly a year into a two-year Regulatory Sandbox for Cell-Cultivated Products, sponsored by the Department for Science, Innovation and Technology and funded with £1.6 million from the government's Engineering Biology Sandbox Fund, with a goal of completing safety assessments for two cell-cultivated products by 2027. The Medicines and Healthcare products Regulatory Agency has a comparable engineered-phage sandbox backed by roughly £921,000 from the same fund. Notably, OPSS's cosmetics pilot does not appear on published lists of Engineering Biology Sandbox Fund awards alongside the FSA and MHRA projects, which suggests it may be running on OPSS's own budget rather than through that DSIT grant pot, a distinction OPSS has not yet clarified publicly.

The programme sits under the government's December 2023 Vision for Engineering Biology, a ten-year, £2 billion ambition to make the UK a global leader in the field by 2030. UK biotech drew £1.23 billion in venture capital in the first half of 2025 alone, and the synthetic-biology cosmetics segment specifically is forecast to grow at roughly 17.9% a year toward $3 billion in value by 2030. For OPSS, the near-term test is narrower than any of those figures: whether a company using cell culture or precision fermentation can walk through its Expression of Interest process before the 4 December deadline and come out the other side with a clearer path to market than the standard regulatory queue offers.